Summary
All eye drops raise problems of local tolerance, but with variable frequencies. They can induce pain on instillation, allergic reactions, delayed healing, punctate keratitis, disturbances of lacrimal secretion, disturbances of accommodation (especially the parasympathomimetics) and local pigmentation after prolonged use. Corticosteroids are associated with 2 major risks: chronic glaucoma and cataract, initially reversible if treatment is stopped. There is still a major risk of corneal herpes with corticosteroids. It is important to be aware of these local problems as they are responsible for poor patient compliance.
The systemic effects essentially concern the agonists and antagonists of the autonomic nervous system. β-Blocker eye drops can cause bronchospasm, heart failure, syncope and psychiatric disorders, especially at high doses and with nonselective β-blockers. These consequences are usually related to failure to comply with the prescribing precautions. α-Adrenergic agonists, which exert dose-dependent effects, can induce hypertensive crises or angina attacks. Apart from patients at risk (children under the age of 30 months and the elderly), parasympathomimetics cause few systemic adverse effects; anticholinesterases, which have curare-like properties, are contraindicated for 6 weeks before general anaesthesia. In the very young and the very old, atropinic eye drops carry a risk of cardiovascular collapse and neuropsychiatric disturbances. Problems may also occur with other classes of drugs such as anti-infectives, antiseptics, anti-inflammatories and contact lens products. Nevertheless, it is clear that this form of treatment is generally very well tolerated in relation to the volume of eye drops prescribed by ophthalmologists each day.
Similar content being viewed by others
References
Abraham D, Robin A, Pollack I, de Faller J, de Santis L. The safety and efficacy of topical 1% ALO 2145 (p-amino Clonidine hydrochloride) in normal volunteers. Archives of Ophthalmology 105: 1205–1207, 1987
Abraham SV. Intraepithelial cyst of the iris. American Journal of Ophthalmology 37: 327, 1954
Abrams SM, Degnan TJ, Vinceguerra V. Marrow aplasia of chloramphenicol eye ointments. Archives of Internal Medicine 140: 576–577, 1980
Adler AG, MacElwain GR, Merli GJ, Martin JH. Systemic effects of eye drops. Archives of Internal Medicine 142: 2293–2294, 1982
Ahmad S. Cardiopulmonary effects of timolol eye drops. Lancet 2: 1028, 1979
Alvarro ME. Effects other than infection of sulfonamides compounds. Archives of Ophthalmology 29: 615–632, 1943
André F, Bielefeld P, Besancenot JF, Belleville I, Sgro C, et al. Fausse inocuité des collyres: a propos d’une observation de thyrotoxicose induite par l’iode. Thérapie 43: 431–432, 1988
Atkins JM, Pugh BR, Timewell R. Cardiovascular effects of topical β-blockers during exercise. American Journal of Ophthalmology 101: 535–541, 1985
Bacin F, Kantelip B. Un cas de calcul du sac lacrymal. Journal Français d’Ophthalmologie 4: 113–116, 1981
Ball S. Congestive heart failure from ocular betaxolol. Archives of Ophthalmology 105: 320, 1987
Basu PK. Toxic effects of drugs on the corneal epithelium: a review. Journal of Toxicology — Cutaneous and Ocular Toxicology 2: 205–227, 1983–1984
Bechetoille P. Les eicosanoides. In Demailly (Ed.) Traitement actuel du glaucome primitif à angle ouvert, pp. 211–219, Masson, Paris, 1989
Benitah E, Chatelain C, Cohen F, Herman D. Fibrose retropér-itonéale: effet systémique d’un collyre β-bloqueur. Presse Médicale 16: 400, 1987
Birkhimer LJ, Jacobson PA, Olson J, Goyette DM. Ocular scopolamine induced psychosis. Journal of Family Practice 18: 464–469, 1984
Black RL, Oglesby RB, Von Sallmann L, von Bunim JJ. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatic arthritis. Journal of the American Medical Association 10: 166–171, 1960
Bleckman H, Dorow P. Therapeutische Konzequenzen einer Glaucomabehandlung mit unterschiedliches β-Blockern bei Patienten mit obstruktiver Atemwegserkrankung. Klinische Monatsblatter für Augenheilkunde 188: 568–572, 1986
Bourgeois JA. Depression and topical ophthalmic β-adrenergic blockade. Journal of the Optometric Association 62: 403–406, 1991
Brandt JD, 233Wittpen JR, Katz LJ, Steinmann WN, Spaeth GL. Conjunctival impression cytology in patients with glaucoma using long term topical medications. American Journal of Ophthalmology 112: 297–301, 1991
Brazier DJ, Hirching RA. Atypical band keratopathy following long term pilocarpine treatment. British Journal of Ophthalmology 73: 294–296, 1989
Britman NA. Cardiac effects of topical timolol. New England Journal of Medicine 300: 566, 1979
Buckley M-T, Goa KL, Clissold SP. Ocular betaxolol: a review of its pharmacological properties and therapeutic efficacy in glaucoma and ocular hypertension. Drugs 40: 75–90, 1990
Burns C. Indomethacin reduced corneal sensitivity, and corneal deposits. American Journal of Ophthalmology 66: 825–835, 1968
Caprioli J. Potential new drugs for glaucoma. In Sherwood & Spaeth (Eds) Complications of glaucoma therapy, pp. 77–88, Slack Inc., Thorofare, 1990
Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections. Drugs 23: 329–353, 1982
Cervantes R, Hernandez y Hernandez H. Pulmonary and heart rate changes associated with non selective β-blocker therapy. Journal of Toxicology — Cutaneous and Ocular Toxicology 5: 185–193, 1986
Chamberlain TJ. Myocardial infarction after ophthalmic betaxolol. New England Journal of Medicine 321: 1342, 1989
Coakes RL, Mackie IA, Seal DV. Effects of long term treatment with timolol on lacrimal gland function. British Journal of Ophthalmology 65: 603–605, 1981
Colin HB. Ultrastructural changes to corneal stromal cells due to ophthalmic preservatives. Acta Ophthalmologica 64: 72–78, 1986
Collignon-Brach J. Les sympathomimétiques. In Demailly (Ed.) Traitement actuel du glaucome chronique à angle ouvert, pp. 114–120, Société Française d’Ophthalmologie, Masson, Paris, 1989
Collin J, Tournoux A, Chastel C, Renard G. Kératite herpétique superficielle: traitement comparatif en double insu par acyclovir et idoxuridine. Nouvelle Presse Médicale 10: 2969–2975, 1981
Corwin ME, Spencer WH. Conjunctival melanin deposition, a side effect to topical epinephrin therapy. Archives of Ophthalmology 69: 317–321, 1963
Demailly Ph. In Demailly (Ed.) Traitement actuel du glaucome chronique à angle ouvert, pp. 199–206, Société Française d’Ophthalmologie, Masson, Paris, 1989
Demailly Ph, Blotiere JP. La cataracte cortisonique. In Demailly (Ed.) Oeil et cortisone, pp. 301–319, Masson, Paris, 1975
Demailly Ph, Dureuil J. Complications neuro-ophthalmologiques de la corticothérapie. In Demailly (Ed.) Oeil et cortisone, pp. 335–340, Masson, Paris, 1975
Demailly Ph, Hamard H, Luton JP. Oeil et cortisone: rapport à la Société Française d’Ophthalmologie, pp. 303–319, Masson, Paris, 1975
Demailly Ph, Kretz G. Les glaucomes iatrogèniques. In Entretiens de Bichat (Thérapeutique), pp. 114–118, Masson, Paris, 1990
De Santis J, Polansky JR, Bruce L. Relative differences in beta receptor activity between the cardioselective β-blocker, betaxolol, and nonselective β-blockers. Proceedings of the XXVth International Congress of Ophthalmology, Rome, May 4–10, 1986, pp. 1501–1505, Khugler & Ghedini, Amsterdam, 1987
Dorigo T, Cerin O, Fracasso G, Altafin R. Cardiovascular effects of befunolol, betaxolol and timolol eye drops. International Journal of Clinical Pharmacological Research 10: 163–166, 1990
Duncan T. Side effects of ocular timolol. American Journal of Ophthalmology 95: 562–563, 1983
Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, et al. The effects of topical betaxolol on lung function in asthmatic subjects. American Review of Respiratory Diseases 133: 264–268, 1986
Epstein E, Kaufman I. Systemic pilocarpine toxicity from overdosage. American Journal of Ophthalmology 59: 109–115, 1965
Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Annals of Internal Medicine 112: 120–125, 1990
Fellman RL, Starita RJ. Ocular and systemic side effects of topical cholinergic and anticholinesterase drugs. In Sherwood & Spaeth (Eds) Complications of glaucoma therapy, pp. 6–18, Slack Inc., Thorofare, 1990
Fraunfelder FT, Bagby GC, Kelly DJ. Fatal aplastic anaemia following topical administration of ophthalmic chloramphenicol. American Journal of Ophthalmology 99: 356–360, 1982
Fraunfelder FT, Meyer SM. Systemic reactions to ophthalmic drug preparations. Medical Toxicology 2: 287–291, 1987
Fraunfelder FT, Meyer SM, Menacker SJ. Alopecia possibly secondary to topical ophthalmic β-blockers. Journal of the American Medical Association 263: 1493–1494, 1990
Fraunfelder FT, Scafidi AF. Possible averse effects from topical 10% phenylephrine. American Journal of Ophthalmology 85: 447–453, 1978
George JL. Les altérations cornéennes conjonctivales et lacrymales. In Raspiller et al. (Eds) Les effets indésirables des médicaments en ophthalmologie. Bulletin des Sociétés d’Ophthalmologie de France, rapport annuel, pp. 109–143, Masson, Paris, 1985
Gerber SL, Cantor LB, Brater DC. Systemic drug interactions with topical glaucoma medications. Survey of Ophthalmology 5: 205–218, 1990
Gerling J, Pfeiffer N, Lippa E, Brunner Ferber F, Grehn F. Local carbonic anhydrase inhibitors MK 927 and MK 417: effects and tolerance. Fortschritte der Ophthalmologie 87: 692–695, 1990
Germain ML, Roca F, Briois F, Kalis B, Choisy H. Aggravation d’un psoriasis sous collyre au timolol. Thérapie 47: 433–437, 1992
Giuffre G. The effects of prostaglandin F2 alpha in the human eye. Graefe’s Archives of Clinical and Experimental Ophthalmology 222: 139–141, 1985
Gottschalk H, Stone OJ. Stevens Johnson syndrome from ophthalmic sulfonamide. Archives of Dermatology 112: 513–514, 1976
Gronvall H. On argyrosis and concretions in the lacrimal ducts. Ophthamologia 21: 247, 1944
Hachet E. Les cataractes. In Raspiller et al. (Eds) Les effets indésirables des médicaments en ophthalmologie, Bulletin des Sociétés d’Ophthalmologie de France, rapport annuel, pp. 87–107, 1985a
Hachet E. Les glaucomes. In Raspiller et al. (Eds) Les effets indésirables des médicaments en ophthalmologie, Bulletin des Sociétés d’Ophthalmologie de France, rapport annuel, pp. 49–73, 1985b
Harris LS, Greinstein SH, Bloom AF. Respiratory difficulties with betaxolol. American Journal of Ophthalmology 102: 274, 1986
Havener WH. Ocular pharmacology, pp. 370–373, C.V. Mosby, St Louis, 1983
Henkes HE, Waubke TN. Keratitis from abuse of corneal anaesthetics. British Journal of Ophthalmology 62: 62, 1978
Hodapp E, Kolker AE, Kass MA. The effect of topical Clonidine on intraocular pressure. Archives of Ophthalmology 99: 1208–1211, 1981
Huang TC, Lee DA. Punctal occlusion and topical medications for glaucoma. American Journal of Ophthalmology 107: 151–155, 1989
Hugues FC, Le Jeunne Cl, Munera Y, Dufier JL. Comparaison des collyres au Cartéolol et au métipranolol sur les fonctions ventilatoires et cardiovasculaires de l’asthmatique. Journal Français d’Ophthalmologie 10: 485–490, 1987
Hugues FC, Le Jeunne Cl, Munera Y, Dufier JL. Evaluation des effets systémiques du maléate de timolol en gouttes oculaires. Journal Français d’Ophthalmologie 8: 389–394, 1985
Hugues FC, Le Jeunne Cl, Salem A, Matte JC. Effects of β-adrenoceptors blocking eye drops in patients with chronic bronchitis. Thérapie 47: 211–215, 1992
Jacobs RL, Rake W, Fournier C. Potentiated anaphylaxis in patients with drug induced β-adrenergic blockade. Journal of Allergy and Clinical Immunology 68: 125–127, 1981
Johnson DH, Epstein DL, Ailen RC, Boyssmith J, Campbell D, et al. A one year multicenter clinical trial of pilocarpine gel. American Journal of Ophthalmology 97: 723–729, 1984
Kass M, Mandel A, Goldberg I, Pine M, Becker B. Dipivefrine and epinephrine treatment of elevated intraocular pressure. Archives of Ophthalmology 97: 1866–1868, 1979
Khurana AK, Ahluwalia BK, Rajan C, Vohra AK. Acute psychosis associated with topical cyclopentolate hydrochloride. American Journal of Ophthalmology 91: 105–106, 1988
Kilp H, Heisig-Salentin B, Poss W, Thade C. Acute and chronic influence of benzalkonium chloride as a preservative. In Hockwin (Ed.) Drug induced side effects and ocular toxicology, Concepts in toxicology, Vol. 4, pp. 59–63, Karger, Basel, 1987
Kooner KS, Zimmerman TJ. Clinical ocular pharmacology: some overlooked features. Ophthalmology Clinics of North America 2: 1–14, 1989
Laroche P. Les syndromes secs oculaires. In Raspiller et al. (Eds) Les effets indésirables des médicaments en ophthalmologie, Bulletin des Sociétés d’Ophthalmologie de France, rapport annuel, pp. 147–166, 1985
Larricart P. Les affections rétiniennes. In Raspiller et al. (Eds) Les effets indésirables des médicaments en ophthalmologie, Bulletin des Sociétés d’ Ophthalmologie de France, rapport annuel, pp. 193–211, 1985
Lass HJ, Thoft RA, Dohlman CH. Idoxuridine induced conjunctival cicatrisation. Archives of Ophthalmology 101: 747–750, 1983
Lavat Ph. Les myotiques. In Demailly (Ed.) Traitement actuel du glaucome primitif à angle ouvert, pp. 102–111, Masson, Paris, 1989
Lebuisson DA, Aron JJ, Coudert JL. Les accidents des médicaments ophthalmologiques. Revue du Praclicien 32: 57–63, 1982
Lee VH. Topical ocular drug delivery: recent advances and future perspectives. Pharmacy International 6: 135–137, 1985
Le Jeunne Cl, Bringer L, Munera Y, Hugues FC. Effets cardiovasculaires des collyres au timolol, au Cartéolol, au métipranolol et au bétaxolol chez le sujet âgé. Thérapie 43: 89–92, 1988
Le Jeunne Cl, Munera Y, Hugues FC. Systemic effects of 3 β-blocker eyedrops: comparison in healthy volunteers of β-1 and β-2 adrenoceptor inhibition. Clinical Pharmacology and Therapeutics 47: 578–583, 1990
Le Jeunne Cl, Munera Y, Hugues FC. Collyre au bétaxolol chez l’asthmatique. Revue des Maladies Respiratoires 8: 420–421, 1991
Leroy MP, Cantincau D, Brasdcfcr D, Courtcville H. Les incidents de la néosynéphrine. Bulletin des Sociétés d’Ophthalmologie de France 89: 243–245, 1989
Locffler M, Hornbass A. Hazards of unitdosc artificial tear preparations. Archives of Ophthalmology 108: 639–640, 1990
Lopitaux R, Herman R, Plane C. Bradycardie induite par un collyre β-bloqueur chez une personne âgée. Revue de Gériatrie 9: 433–434, 1984
Lumbroso P, Serpin G. L’intolérance aux collyres et aux produits d’entretien des lentilles de contact. Année Thérapeutique et Clinique en Ophthalmologie 39: 102–112, 1988
Lynch MG, Whitson JT, Brown RH, Nguyen H, Drake MM. Topical β-blocker therapy and central nervous system side effects, a preliminary study comparing betaxolol and timolol. Archives of Ophthalmology 106: 908–911, 1988
MacGill J, Tormey P. Use of acyclovir in herpetic ocular infections. American Journal of Medicine 72: 286–289, 1982
Mackie B, Mackie LE. Systemic lupus erythematosus — dermatomyositis induced by sulfacetamide eye drops. Australian Journal of Dermatology 420: 49–50, 1979
MacMahon CD, Shaffer RN, Hoskins HD, Hetherington J. Adverse effects experienced by patients taking timolol. American Journal of Ophthalmology 88: 736–738, 1979
Markman HD, Rosenberg P, Dettbarn W. Eye drops and diarrhoea: diarrhoea as the first symptom of ecothiophate iodide toxicity. New England Journal of Medicine 271: 197–198, 1964
Maurice DM. Kinetics of topically applied ophthalmic drugs: biopharmaceutical, technological and clinical aspects. Fidia Research Series 11: 19–25, 1985
Meuche C, Heidrich H, Bleckmann H. Reynaud syndrome nach Timolol-haltigen Augentropfen. Fortschritte der Ophthalmologie 87: 45–47, 1990
Mignot G, Laroche L. Prendre en compte les effets indésirables systémiques des β-bloqueurs en collyre. Prescrire 11: 45–47, 1991
Nehme S, Trouve O, Renard G. La gentamycine en ophthalmologie: spectre, indications, voies d’administration, toxicité et tolérance. Journal Français d’Ophthalmologie 10: 595–605, 1980
Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution. American Journal of Ophthalmology 102: 606–611, 1986
Nelson W, Kuritsky JN. Early post marketing surveillance of betaxolol hydrochloride: September 1985–September 1986. American Journal of Ophthalmology 10: 592, 1987
Newcomb RD, Ranson FG. Adverse systemic effects of ocular drug therapy. In Bartlett et al. (Eds) Clinical ocular pharmacology, pp. 941–960, Butterworth, Boston, 1984
North RV, Kelly ME. A review of the uses and adverse effects of topical administration of atropine. Ophthalmic and Physiological Optics 7: 109–114, 1987
Olson RJ, Bromberg BB, Zimmermann TJ. Apneic spets associated with timolol therapy in neonate. American Journal of Ophthalmology 88: 120, 1979
Olson RJ, White GL. Preservatives in ophthalmic topical medications: a significant cause of disease. Cornea 9: 363–364, 1990
Orlando RG. Adverse systemic reactions of ocular drops. Ohio Slate Medical Journal 80: 747–749, 1984
Orlando RG. Clinical depression association with betaxolol. American Journal of Ophthalmology 102: 275, 1986
Ourgaud AG, Ourgaud M. Dangers oculaires de la corlicolhérapie locale ou générale. Gazette Médicale 91: 59–63, 1984
Pape LG, Forbes M. Retinal detachment and miotic therapy. American Journal of Ophthalmology 85: 558–566, 1978
Pichon P, Moreau G. Complications cornéennes par usage de collyre a l’indométacinc. Bulletin des Sociétés d’Ophthalmologie de France 90: 449–451, 1990
Plane Ch. Les β-bloqucurs locaux. In Demailly (Ed.) Traitement actuel du glaucome primitif à angle ouvert, pp. 166–187, Masson, Paris, 1989
Plane Ch, Boumier A. Quatre ans de traitement prolongé des glaucomes chroniques par le collyre au timolol. Journal Français d’Ophthalmologie 11: 751–756, 1981
Poggio EC, Glynn RJ, Schein OD, Seddon JM, Shannon MJ, et al. The incidence of ulcerative keratitis among users of daily wear and extended wear soft contact lenses. New England Journal of Medicine 321: 779–783, 1989
Polak BC. Chloramphenicol in ophthalmology. Geneesmiddelen-bulletin 18: 31–32, 1984
Polak BC. Drugs used in ocular treatment. In Dukes (Ed.) Meyler’s side effects of drugs, Vol. 2, pp. 988–998/133-158, Elsevier, Amsterdam, 1988, 1990
Prakash UD, Rosenow EC. Pulmonary complications from ophthalmic preparations. Mayo Clinic Proceedings 65: 521–529, 1990
Reyes P, Dwyer BA, Schwarzmann RJ, Sacchetti T. Mental status changes induced by eye drops in dementia of the Alzheimer type. Journal of Neurology, Neurosurgery and Psychiatry 50: 113–115, 1987
Riedl B, Reitmeier G, Heese A, Hahn H, Peters KP, et al. Type IV allergies to components of ophthalmologia. Klinische Monatsblauer für Augenheilkunde 198: 251–254, 1991
Romo Santos E. Glaucoma por corticoides. Archivos de la Associacion para Evitar la Ceguera en Mexico 14: 63–69, 1972
Rosales T, Isenberg S, Leake R, Everett S. Systemic effects of mydriatics in low weight infants. Journal of Pediatric Ophthalmology and Strabismus 18: 42–44, 1981
Rosenthal RL, Blackmann A. Bone marrow hypoplasia following use of chloramphenicol eye drops. Journal of the American Medical Association 191: 136–137, 1965
Rosenwasser GO. Complications of topical ocular anesthetics. International Ophthalmologic Clinics 29: 153–158, 1989
Rumelt MB. Blindness from misuse of over-the-counter eye medications. Annals of Ophthalmology 20: 26–30, 1988
Schein OD, Wassonn PJ, Boruchoff SA, Kenyon KR. Microbial keratitis associated with contaminated ocular medications. American Journal of Ophthalmology 105: 361–365, 1988
Schoene RB, Abuan T, Ward RL, Beasley CH. Effects of topical betaxolol, timolol and placebo on pulmonary function in asthmatic bronchitis. American Journal of Ophthalmology 97: 86–92, 1984
Sheehan GJ, Kutzner MR, Chin WB. Acute asthma attack due to ophthalmic indomethacin. Annals of Internal Medicine 111: 337–338, 1989
Shore HJ, Fraunfelder FT, Meyer SM. Psychiatric side effects from topical ocular timolol, a β-adrenergic blocker. Journal of Clinical Psychopharmacology 7: 264–267, 1987
Sobol WM, MacCrary JA. Ocular aesthetic properties and adverse reactions. International Ophthalmologic Clinics 29: 195–199, 1989
Solosko D, Smith RB. Hypertension following 10% phenylephrine ophthalmic. Anesthesiology 36: 187–189, 1972
Sorkin EM, Ward A. Ocular sodium cromoglycate: an overview of its therapeutic efficacy in allergic eye diseases. Drugs 31: 131–132, 1986
Spencer WH, Garron LK, Conteras F, Hayes TL, Lai C. Endogenous and exogenous ocular and systemic silver deposition. Transactions of the Ophthalmological Societies of the United Kingdom 100: 171–178, 1980
Starita RJ, Fechtner RD, Fellman RL. Ocular and systemic side effects of: topical epinephrine and dipivefrin. In Sherwood & Spaeth (Eds.) Complications of glaucoma therapy, pp. 19–32, Slack Inc., Thorofare, 1990
Tabbara KF, Veirs ER. Corneal white plaques caused by sulfacetamide eye drops. American Journal of Ophthalmology 98: 378–380, 1984
Thomas J, Grangongos E, Blair N, Lapsus J. Correlation with epinephrine and macula edema in aphakic eyes. Archives of Ophthalmology 95: 152, 1977
Vadot E, Piasentin D. Fréquence des allergies de contact aux collyres en milieu hospitalier: résultats d’une étude prospective. Journal Français d’Ophthalmologie 9: 41–43, 1986
Van Burskirk EM. Corneal anaesthesia after timolol maleate therapy. American Journal of Ophthalmology 88: 739–743, 1979
Van Burskirk E. Adverse reactions from timolol administration. Ophthalmology 87: 447–450, 1980
Verkijk A. Worsening of myasthenia gravis with timolol maleate eye drops. Annals of Neurology 17: 211–222, 1985
Vinti H, Chichmanian RM, Fournier JF, Pesche A, Taillon B, et al. Complications systémiques des collyres β-bloquants: à propos de 6 cas. Revue de Médecine Interne 10: 41–44, 1989
Watkins RW, Baum T, Tedesco RP, Pula K, Barnett A. Systemic effects resulting from topical ocular administration of SCH 33861, a novel ACE inhibitor ocular hypotensive agent. Journal of Ocular Pharmacology 4: 93–100, 1988
Wilensky JT, Woodward HJ. Acute systemic hypertension after conjunctival instillation of phenylephrine hydrochloride. American Journal of Ophthalmology 76: 156–157, 1973
Wilhelmus KR, MacCulloch RR, Gross RL. Dendritic keratopathy associated with β-blocker eye drops. Cornea 9: 335–337, 1990
Wilson RP. Complications of ophthalmic aesthesia. In Sherwood & Spaeth (Eds) Complications of glaucoma therapy, pp. 133–156, Slack Inc., Thorofare, 1990
Zografos L. Enqûete internationale sur l’incidence des accidents graves ou fatals pouvant survenir lors d’une angiographie fluoresceinique. Journal Français d’Ophthalmologie 6: 495–499, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hugues, FC., Le Jeunne, C. Systemic and Local Tolerability of Ophthalmic Drug Formulations. Drug-Safety 8, 365–380 (1993). https://doi.org/10.2165/00002018-199308050-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199308050-00004